PT  - JOURNAL ARTICLE
AU  - PATRIZIA MONDELLO
AU  - VINCENZO PITINI
AU  - CARMELA ARRIGO
AU  - ENRICO DERENZINI
AU  - MICHAEL MIAN
TI  - <sup>90</sup>Y-Ibritumomab Tiuxetan Consolidation After Autologous Stem Cell Transplantation Improves Survival of Patients with Intermediate-/High-risk Diffuse Large B-cell Lymphoma Not Responding Adequately to First-line Treatment
DP  - 2014 Sep 01
TA  - Anticancer Research
PG  - 5121--5125
VI  - 34
IP  - 9
4099  - http://ar.iiarjournals.org/content/34/9/5121.short
4100  - http://ar.iiarjournals.org/content/34/9/5121.full
SO  - Anticancer Res2014 Sep 01; 34
AB  - Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma entity whose prognosis for high-risk patients is poor. Aggressive salvage treatments to improve patient outcome have been unsatisfactory. Therefore, we evaluated the efficacy of yttrium-90-ibritumomab tiuxetan (Zevalin®; 90Y-IT) consolidation after early salvage chemotherapy with autologous stem cell transplantation. Thirty-seven patients with intermediate-high risk DLBCL not in complete remission (CR) after three cycles of rituximab, cyclophosphomide, doxorubicin, vincristine and prednisone (R-CHOP) were assessed retrospectively. After early salvage treatment, 70% achieved CR and 30% partial remission. Twenty patients underwent additional consolidation with 90Y-IT. During the 3-year follow-up, 50% in the 90Y-IT-treated group experienced relapse compared to 82.3% in the other cohort (p=0.002). Progression- and disease-free survival were significantly longer in the 90Y-IT group. However, probably due to the relatively short follow-up period, no difference in overall survival was observed. 90Y-IT consolidation after early salvage chemotherapy improves treatment responses and reduces the percentage of relapses without significant additional toxicities.